Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 102, Issue 11, Pages 1949-1957
Publisher
Wiley
Online
2011-08-04
DOI
10.1111/j.1349-7006.2011.02054.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib
- (2011) Takeshi Yuasa et al. BJU INTERNATIONAL
- Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
- (2011) Viktor Gruenwald et al. BMC CANCER
- Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
- (2011) F Farace et al. BRITISH JOURNAL OF CANCER
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Size Is a Potential Predictor of Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer
- (2011) Takeshi Yuasa et al. UROLOGY
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
- (2010) S. Patil et al. ANNALS OF ONCOLOGY
- ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
- (2010) T. Mizuno et al. ANNALS OF ONCOLOGY
- Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
- (2010) Aristotelis Bamias et al. BMC CANCER
- Myelosuppression by sunitinib is flt-3 genotype dependent
- (2010) N P van Erp et al. BRITISH JOURNAL OF CANCER
- Hypothyroidism in patients with renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER
- Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene
- (2010) Haruka Kawahara et al. CANCER SCIENCE
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
- (2010) Camillo Porta et al. KIDNEY INTERNATIONAL
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
- (2009) Nielka P. van Erp et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Telmisartan pharmacokinetics in Japanese renal transplant recipients
- (2008) Masatomo Miura et al. CLINICA CHIMICA ACTA
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
- (2008) S. Shukla et al. DRUG METABOLISM AND DISPOSITION
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now